DOCSLIB.ORG

Diagnostic Reference Levels (Drls) for Radiopharmaceuticals Administered in Nuclear Medicine — Four-Year Experience with Their Use

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Diagnostic Reference Levels (Drls) for Radiopharmaceuticals Administered in Nuclear Medicine — Four-Year Experience with Their Use Diagnostic reference levels (DRLs) for radiopharmaceuticals administered in nuclear medicine — four-year experience with their use Vaclav Husali, Pavel Koranda, Zuzana PaSkova X), Karia Petrovd J), Zdenek Prouza J) Department of Nuclear Medicine, University Hospital and Palacky University, Olomouc State Office for Nuclear Safety (SONS) S), Prague, Czech Republic Introduction of DRLs levels in Czech Republic (CR). DRLs were established four years ago using the results of the national questionnaire survey on the type and amount of administered radiopharmaceuticals (RP) performed during 1996. DRLs were implemented in SONS Regulation No. 184/1997 Coll. for 92 nuclear medicine (NM) procedures, e. g. for "mTc- phosphates bone scintigraphy DRL was 800 MBq, for "mTc-HMPAO brain scintigraphy 800 MBq, for "mTc-MIBI planar scintigraphy of myocardial perfusion 600 MBq, for 2OIT1 SPECT myocardial perfusion 110 MBq, for ""Tc-DMSA kidney scintigraphy 200 MBq etc. DRLs guidelines. In order to facilitate the implementation of DRLs into the clinical practice an explanatory information (guidelines) was prepared about the purpose, significance and correct use of DRLs; the principles given! in BSS [1] and ICRP 73 [2] were taken into account. There are two inappropriate regions of administered activity of RP to patients. The upper inappropriate region is connected with a unnecessarily high radiation burden of a patient without improving a quality of scintillation camera images. The lower inappropriate region results in a poor image quality which may lead to serious diagnostic errors and/or repetition of an examination. DRL indicates the upper boundary of the region of acceptable practice in which the optimal activity of RP administered to a patient is chosen according to the scintillation camera geometry (I, 2, 3 detectors), collimators, time available for the examination etc.; optimal value of RP activity below DRL should assure the lowest necessary dose to achieve the diagnostic information needed. DRLs are applied to a typical 70 kg patient and should be adjusted to account for significantly under-weight and over-weight patients. Activity A of RP administered to a patient having a weight W different from 70 kg (< 60 kg and > 85 kg) is recommended to be 7 calculated as A = A70 x F where F = W° /70 is the scaling factor derived from body surface area. Factor F for children is practically identical with that given in the known EANM recommendation [3]. Thus, activities recommended to be administered to children and adults are determined consistently on a body surface area basis. Our guidelines points out, in accordance with BBS [1] and ICRP 73 [2], that DRL is not a limit which could not be exceeded. DLR should not be exceeded in routine clinical practice; higher levels are acceptable in individual - relatively rare cases - which are justifiable by a patient's clinical condition (other diseases, complications etc.). Check of DRLs practical use. With regard to the prepared amendment to SONS Regulation No. 184/1997 it has been necessary to check how DRLs have been respected in clinical practice. Therefore, two surveys were conducted in 1998 and 2001. The first more detailed questionnaire circulated to 49 departments of NM in CR focussed on three major topics: an observance of DRLs in clinical practice, a method used for the determination of RP activity administered to patients having a weight different from 70 kg and a percentage of examinations in which DRLs had to be exceeded on clinical grounds (with the exception of examinations requiring administration of higher activities due to a patient's weight above 70 kg). The complete response rate was 82 % (40/49). 26 departments which had no remarks on DRLs in SONS Regulation No. 184/1997 were supposed to adhere to them without difficulties. The remaing ones complained that DRLs for some examinations were too low: whole-body planar 67Ga scintigraphy 150 MBq, thyroid gland m 99m " TcO4 scintigraphy 150 MBq, whole-body scintigraphy (tumours) with Tc labelled monoclonal antibodies 500 MBq and others. XXIV DRO Demanovskii dolina 82 SK0PK018^ 33 departments reported the use of the known procedure recommended by EANM [3] for determining RP activities administered to children and of that for persons having weight higher than 85 kg which was recommended in our DRL guidelines mentioned above. Only 5 departments determined RP activity according to a patient's weight. 23 departments announced no cases of exceeding DRLs with regard to patient's condition and other circumstances. The estimate of a percentage of these cases given by 17 departments ranged from 0.5 % to 10 %. The second questionnaire was distributed in 2001 several months ago before working out the first proposal of the table containing modified values of DRL to be included into the amendment to SONS Regulation No. 184/1997 Coll. The purpose of this survey performed after almost three years since the first one was to find out latest comments on DRLs. Of 49 departments only 20 ones answered; the low response rate was not a surprise because in our covering letter no reply was required in case that a department was satisfied with DRLs and had no comments. Of 20 replies 5 ones contained no remarks, answers of remainig 15 departments helped us to improve the table for the proposed SONS Regulation. DRLs in the amendment to SONS Regulation No.184/1997 Coll. Table 1 contains DRLs proposed to be included into the amendment to this regulation. Using the results of questionnaires and, in some cases, regarding DRLs valid abroad [4, 5, 6], too, the following changes were performed: - eight new radiopharmaceuticals and examinations were included (18F-FDG, 123I iomazenil, 123IIBZM, examination of sentinel nodes and others; 99m - DRL was increased for eight examinations: Tc04 scintigraphy of thyroid gland from 150 MBq to 200 MBq, "mTc-MIBI planar scintigraphy of parathyroid from 400 MBq to 750 MBq, 99mTc-antibodies tumours and inflammation imaging from 600 MBq to 800 MBq etc.; m 99m DRL was decreased for seven examinations: " TcO4 or Tc-DTPA dynamic brain scintigraphy from 800 MBq to 600 MBq,, "Tc-MAA, microspheres lung scintigraphy from 200 MBq to 150 MBq, "mTc-DMSA kidney scintigraphy from 200 MBq to 150 MBq etc.); - two examinations, 133Xe lungs ventilation and mI bengal rose chromextr. function of liver, were omitted; some minor modifications were carried out to improve the arrangement of the table. The increase in DRLs for some examinations was substantiated very carefully taking pains to counterbalance it by their decrease for other examinations where reasonable. Conclusion. The use of DRLs, as a component of a Quality Assurance Programme supervised in departments of NM by SONS, appears to aid in the optimisation of radiation protection for patients undergoing NM procedures. References [1J Safety Series No. 115: International Basic Safety Standards for Protection against Ionizing Radiation and for the Safety of Radiation Sources. Vienna, IAEA 1996. [2] ICRP Publication 73: Radiological Protection and Safety in Medicine. Annals of the ICRP, 26, 1996. Oxford, Elsevier Science Ltd. 1996. [3] Paediatric Task Group of the European Association of Nuclear Medicine (EANM): A radiopharmaceutical schedule for imaging in paediatrics. Eur. J. Nucl. Med. 17, 1990, 127 - 129. [4] Notes for Guidance on the Clinical Administration of Radiopharmaceuticals and Use of Sealed Radioactive Sources. Chilton, NRPB 1998. [5] Schtcha, H.: Diagnostische Referenzwerte in der Nuklearmedizin Empfehlungen der Strahlenschutzkommission verabschiedet in der 167. Sitzung der Strahlenschutzkommission am 6./7. Juli 2000. Nuklearmedizin 39 (2000), Nl 18 -Nl 19. [6] Smart, R. C, Towson, J. E.: Diagnostic Reference Activities for Nuclear Medicine Procedures in Australia and New Zealand. Rad. Prot. In Australasia 17, 2000, No.l, 2-14. XXIV DRO Demanovska dolina 83 Table 1 Proposal of diagnostic reference levels in nuclear medicine to be included in amendment to SONS Regulation No. 184/1997 Coll. Examination Radio- Substance, DRL Organ Kind, group nuclide chemical form [MBq] scintigraphy bone (whole - body, three - phases, Tc-99m phosphates 800 SPECT) scintigraphy bone marrow (whole - body, SPECT) Tc-99m nanocolloids 550 brain scintigraphy dynamic Tc-99m TcO4, DTPA 600 planar Tc-99m TcO4, DTPA 600 SPECT Tc-99m TcO4, DTPA, HMPAO, ECD 800 receptors 1-123 Iomazenil, IBZM 200 glucose uptake F-18 F-18-FDG 400 cisternography In-Ill DTPA 40 Yb-169 EDTA 40 thyroid gland uptake 1-131 iodide 0.5 Tc-99m TcO4 40 scintigraphy Tc-99m TcO 200 planar 4 Tc-99m MIBI, DMSA 400 1-123 iodide 20 1-131 iodide 7 Tl-201 chloride 80 whole - body, SPECT C Tc-99m MIBI, DMSA (V) 600 in carcinoma of thyroid ~< 1-131 iodide 300 gland [_ Tl-201 chloride 100 parathyroid scintigraphy gland planar Tc-99m • TcO4 200 Tc-99m MIBI 750 Tl-201 chloride 80 adrenals scintigraphy planar 1-123 MIBG 200 norcholesterol, 1-131 MIBG 20 lungs scintigraphy ventilation Tc-99m aerosol, technegas 1000 Kr-81m gas 6000 perfusion static Tc-99m MAA, microspheres 150 SPECT Tc-99m MAA, microspheres 300 heart myocardial imaging Tc-99m MIBI, tetrofosmin 1000 (SPECT) Tl-201 chloride 110 reinjection Tl-201 chloride 40 viability F-18 FDG 500 ventriculography Tc-99m erythrocytes 800 first pass Tc-99m ,. TcO4, HSA 900 lymphatic radionuclide Tc-99m nanocoloid 150 system lymphography sentinel nodes Tc-99m nanocolloid 100 vessels fibrinogen uptake 1-125 3 radionuclide venography Tc-99m MAA 200 (one extremity) DTPA, 300 radionuclide angiography Tc-99m erythrocytes,
Load more

Recommended publications
  • Quantitative Bone Scintigraphy. a Study in Patients with Prostatic Carcinoma
    i Quantitative Bone Scintigraphy A study in patients with prostatic carcinoma Gunilla Sundkvist \OO -II , Malmö 1991 Organization Document name LUND UNIVERSITY DOCTORAL DISSERTATION Department of Clinical Physiology Date of issue Malmö Allmänna Sjukhus 1991-05-08 S-214 01 Malmö, Sweden CODEN: LUMEDW-f.MEFM-lOlOU-lOO (1991) Authors) Sponsoring organization Gunilla Sundkvist Title and subtitle Quantitative Bone Scintigraphy. A study in patients with prostatic carcinoma. Abstract Quantitative bone scintigraphy was performed in patients with prostatic carcinoma before orchiectomy as well as two weeks, two and six months after operation. The count rate was recorded as serial gamma camera images over the lower thoracic and all lumbar vertebrae from 1 to 240 min and at 24 h after injection of "Tcm-MDP. In almost all abnormal vertebrae an increased count rate was observed within one hour after injection. Most of the vertebrae which were considered normal at 4 h after injection, but had an increased 24 h/4 h ratio developed into abnormal vertebrae later in the study. The patients with normal bone scintigrams showed no change in "Tcm- MDP uptake during the study. The reproducibility of quantitative bone scintigraphy was found to be ± 7% (1 SD). In response to therapy, most of the patients with abnormal bone scintigrams showed an increase in count rate two weeks after operation followed by a decrease to the pre-operative level after two months and a o further decrease after six months. This so called "flare phenomenon" was found to m ta indicate "Tc -MDP in the vascular phase as well as an active bone uptake.
    [Show full text]
  • Three-Dimensional Bone Scintigraphy Using Volume-Rendering Technique and SPECT
    5. Adler LP. Crowe JJ. Al-Kaise NK, Sunshine JL. Evaluation of breast masses and (23) could be used in conjunction with this method to guide axillary lymph nodes with [Ii<F]2-deoxy-2-nuoro-d-glucose. Radiology 1993:187:743- core biopsies of breast masses. Or, a separate removable device 750. that can be fixed to a PET, SPECT or gamma camera bed could 6. Wahl RL. Helvie MA, Chang AE, Andersson I. Detection of breast cancer in women be fabricated. The latter approach would enable these pre after augmentation mammoplasty using fluorine-18-fluorodeoxyglucose PET. J Nucí existing devices to be temporarily converted to emission-guided Med 1994;35:872-875. 7. Khalkhali I, Mena I, Diggles L. Review of imaging technique for the diagnosis of biopsy machines. breast cancer: a new role of prone scintimammography using technetium-99m- sestamibi. Ear J NucíMed 1994;21:357-362. CONCLUSION 8. Kao CH, Wang SJ, Liu TJ. The use of technetium-99m-methoxyisobutylisonitrile A simple method for calculation of the position of radionu- breast scintigraphy to evaluate palpable breast masses. Eitr J Nuc Med 1994;21:432- 436. clide-avid tumors or other photon-emitting bodies utilizing two 9. Khalkhali I, Mena I, Jouanne E, et al. Prone scintimammography in patients with views from tomograph sinograms has been proposed and suspicion of carcinoma of the breast. J Am Coll Surg 1994:178:491-497. 10. Heywang-Köbrunner SH. Contrast-enhanced MR1 of the breast. New York: Basel; experimentally validated. This method has been used to accu 1990.
    [Show full text]
  • Bone Scintigraphy in Acetabular Labral Tears
    ORIGINAL ARTICLE Bone Scintigraphy in Acetabular Labral Tears Warwick Bruce, MB, FRACS, FA Orth A,* Hans Van Der Wall, PhD, FRACP,† Geoffrey Storey, MB, FRACP,† Robert Loneragan, MB, FRANZCR,‡ George Pitsis, MB, Dip Paeds,§ and Siri Kannangara, MB, FRACP¶ acetabular labrum without arthrography has shown poor sen- Background: Acetabular labral tears are an increasingly recog- 6 nized cause of hip pain in young adults with hip dysplasia and older sitivity (30%) and accuracy (36%). MR arthrography is patients with degenerative disease of the hips. required for a definitive imaging diagnosis, leading to an 6 Methods: The authors analyzed retrospectively bone scintigraphy incremental sensitivity of 90% and accuracy of 91%. Ar- in 27 patients with acetabular labral tears diagnosed by MRI/ throscopy also has a high rate of diagnosis and the potential arthroscopy. Analysis was also made of scintigraphy in 30 patients to allow surgical intervention at the same time.7 It is, how- without labral tears being investigated for other causes of hip pain ever, invasive and more technically demanding in the hip for comparison. than at other sites.8 We present the results of bone scintigra- Results: Patients with labral tears had hyperemia of the superior or phy in a series of patients with acetabular labral tears that superomedial aspect of the acetabulum and increased delayed uptake allows a simple screening test before either MR arthrography in either a focal superior pattern or in an “eyebrow” pattern of a or arthroscopy superomedial tear. This pattern was not seen in any other sources of hip pathology. Conclusion: Uptake in the superior or superomedial aspect of the METHODS acetabular rim is characteristic of a labral tear.
    [Show full text]
  • Patterns, Variants, Artifacts & Pitfalls in Conventional Radionuclide Bone
    Patterns, Variants, Artifacts, and Pitfalls in Conventional Radionuclide Bone Imaging and SPECT/CT Gopinath Gnanasegaran, MD,* Gary Cook, MD, FRCR,† Kathryn Adamson, MSc,* and Ignac Fogelman, MD* Bone scintigraphy is one of the most common investigations performed in nuclear medicine and is used routinely in the evaluation of patients with cancer for suspected bone metastases and in various benign musculoskeletal conditions. Innovations in equipment design and other advances, such as single-photon emission computed tomography (SPECT), positron emission tomography, positron emission tomography/ computed tomography (CT), and SPECT/CT have been incorporated into the investiga- tion of various musculoskeletal diseases. Bone scans frequently show high sensitivity but specificity, which is variable or limited. Some of the limited specificity can be partially addressed by a thorough knowledge and experience of normal variants and common patterns to avoid misinterpretation. In this review, we discuss the common patterns, variants, artifacts, and pitfalls in conventional radionuclide planar, SPECT, and hybrid bone (SPECT/CT) imaging. Semin Nucl Med 39:380-395 © 2009 Elsevier Inc. All rights reserved. adionuclide bone scintigraphy is used as a routine falls in radionuclide planar, single-photon emission com- Rscreening test for suspected bone metastases in a number puted tomography (SPECT), and hybrid bone imaging of cancers and for the investigation of many benign muscu- (SPECT/computed tomography [CT]). loskeletal conditions because of its sensitivity, low cost, avail- ability, and the ability to scan the entire skeleton.1,2 In recent years technetium-99m (99mTc)-labeled diphos- Scintigraphic Techniques phonates have become the most widely used radiophar- and Instrumentation: maceuticals [particularly 99mTc methylene diphosphonate Planar, SPECT, SPECT/CT (99mTc-MDP)].1,2 Bone scans have high sensitivity, but spec- ificity is frequently variable or limited.
    [Show full text]
  • A Life-Threatening Disease That Can Go Undetected
    TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM) A LIFE-THREATENING DISEASE THAT CAN GO UNDETECTED ATTR-CM: The Disease • ATTR-CM is a rare condition that is life-threatening, underrecognized, and underdiagnosed1-6 Suspect the Signs of ATTR-CM • The diagnosis of ATTR-CM is often delayed or missed1-3 Detect ATTR-CM Utilizing Nuclear Scintigraphy • Tools used to diagnose ATTR-CM include nuclear scintigraphy (eg, PYP cardiac imaging), endomyocardial biopsy (EMB), and genetic testing4,7-10 PYP = 99mTc-pyrophosphate. ATTR-CM: The Disease UNDERSTANDING TRANSTHYRETIN A CLOSER LOOK AT WILD-TYPE AND HEREDITARY ATTR-CM AMYLOID CARDIOMYOPATHY WILD-TYPE ATTR-CM HEREDITARY ATTR-CM Wild-type ATTR-CM (wtATTR) is idiopathic1 and is Hereditary ATTR-CM (hATTR)* occurs due to a not considered to be a hereditary disease.5 It is mutation in the TTR gene.5 In the United States, (ATTR-CM) thought to account for the majority of all the most common mutation causing ATTR is ATTR-CM cases.3 the valine-to-isoleucine substitution at position 122 (V122I).3 This mutation affects almost exclusively the African American population, with a prevalence of about 3-4%.4,17 Not all patients SOME PATIENT CONSIDERATIONS who carry this mutation will go on to have clinical signs and symptoms of this disease. • Ethnicity: predominantly white1,3 UNDERSTANDING ATTR-CM *Also known as variant ATTR (ATTRv).14 • Mostly men1-3 Amyloidosis is a group of diseases in which amyloid fibrils deposit into the extracellular space of the heart. • Symptom onset typically over the 11 The amyloid fibrils are formed by an aggregation of misfolded proteins.
    [Show full text]
  • Complementary Use of Radiological Skeletal Survey and Bone
    387 ORIGINAL ARTICLE Arch Dis Child: first published as 10.1136/adc.88.5.387 on 1 May 2003. Downloaded from Complementary use of radiological skeletal survey and bone scintigraphy in detection of bony injuries in suspected child abuse S A Mandelstam, D Cook, M Fitzgerald, M R Ditchfield ............................................................................................................................. Arch Dis Child 2003;88:387–390 Aim: To compare the effectiveness of radiological skeletal survey and bone scintigraphy for the detec- tion of bony injuries in cases of suspected child abuse. Methods: All cases with a discharge diagnosis of child abuse that presented to the Royal Children’s Hospital between 1989 and 1998 were retrieved, and those children that had undergone both skel- etal survey and bone scintigraphy (radioisotope bone scan) within a 48 hour period were included in this study. Both examinations followed rigid departmental protocols and protocols remained identical See end of article for throughout the timeframe of the study. The reports of the skeletal surveys and bone scans were retro- authors’ affiliations spectively reviewed by a paediatric radiology fellow and consultant paediatric radiologist. ....................... Results: The total number of bony injuries identified was 124 in 30 children. Of these, 64 were iden- Correspondence to: tified on bone scan and 77 on skeletal survey. Rib fractures represented 60/124 (48%) of the bony Dr S A Mandelstam, injuries and were present in 16/30 children (53%), of which 62.5% had multiple rib fractures. Exclud- Radiology Department, ing rib fractures, there were 64 (52%) bony injuries, of which 33% were seen on both imaging modali- Royal Children’s Hospital, ties, 44% were seen on skeletal survey only, and 25% were seen on bone scans alone.
    [Show full text]
  • Diagnosis of Osteo-Articular Infection in Nuclear Medicine
    Diagnosis of osteo-articular infection in nuclear medicine Dr N Dumarey Dept of Nuclear Medicine ULB - Hôpital Erasme Brussels Some basic principles in Nuclear Medicine Scintigraphy • A tracer is injected (IV) which emits gamma- rays due to radioactive decay. • Radioactivity comes from the inside of the patient, in contrast with X-ray or CT, in which radioactivity is emitted by a device and transmitted through the body. Some basic principles in Nuclear Medicine • Technetium-99m is the most often used tracer in nuclear medicine and is bound to a different ligand in function of the organ under study. – Technetium-labeled MDP (bone scan) – Technetium-labeled HMPAO (brain perfusion scan) – Technetium-labeled MAG3 (nephrogram) – Technetium-labeled MIBI (myocardial perfusion) SPECT • SPECT: Single Photon Emission Computed Tomography • = tomoscintigraphie (Fr) • SPECT images are tomographic acquisitions as in CT. The camera rotates around the patient and acquires data. SPECT • These data are reconstructed into slices in different planes (transversal, coronal and sagittal). • SPECT increases sensitivity and specificity of the scintigraphy. • No need for a new injection of radioactive tracer. Image fusion -> Can improve localization Bone scan X-ray Fusion of scintigraphic lesions Software fusion Leucocyte scan X-ray Fusion Scintigraphy is fused with an other imaging modality performed on a separate device with the help of a software program. SPECT/CT • SPECT/CT is a hybrid camera that couples a SPECT- camera with a CT-scan (hardware fusion). • It resolves the problem of low resolution on scintigraphic imaging and allows to localize lesions more accurately. SPECT/CT SPECT CT Fusion SPECT/CT PET • = Positron Emission Tomography • A PET-tracer emits positrons.
    [Show full text]
  • Appropriate Use Criteria for Bone Scintigraphy in Prostate and Breast Cancer
    Appropriate Use Criteria for Bone Scintigraphy in Prostate and Breast Cancer Kevin J. Donohoe1, Erica J. Cohen1, Francesco Giammarile2, Erin Grady1, Bennett S. Greenspan1, Robert E. Henkin1, John Millstine1, Gary T. Smith1, Sandy Srinivas3, Julie Kauffman1, and Sukhjeet Ahuja1 1Society of Nuclear Medicine and Molecular Imaging; 2European Association of Nuclear Medicine; and 3American Society of Clinical Oncology EXECUTIVE SUMMARY INTRODUCTION Nuclear medicine imaging studies are essential to the di- The following document describes the appropriate use of agnosis and management of many diseases, including neoplastic nuclear medicine bone scintigraphy in patients with breast and disease (1). Modern imaging studies allow noninvasive exami- prostate cancer. The authors have tried to cover the most common nation of anatomic and physiologic processes that often change clinical scenarios for bone scintigraphy in patients with these two patient management and improve outcomes. The ready availabil- common malignancies. However, the reader is reminded that a ity and high sensitivity of medical imaging in conjunction with patient may present with variations of the scenarios covered here, concerns about missed diagnoses has, at times, resulted in in- or with signs or symptoms not described, for which bone appropriate use of the technology. This has resulted in an un- scintigraphy may still be indicated. This document is presented necessary financial burden on the health-care system and in some to assist health-care practitioners considering bone scintigraphy cases unnecessary exposure to ionizing radiation (1–5). Incon- for patients with breast and prostate cancer; however, each patient sistent use of specific imaging procedures for similar clinical is unique, as is each patient’s clinical presentation, and therefore scenarios has prompted a push for consensus documents outlin- this document cannot replace clinical judgement.
    [Show full text]
  • Clinical Use of Quantitative Analysis of Bone Scintigraphy to Assess the Involvement of Arthritis Diseases in Patients with Joint Symptoms
    diagnostics Article Clinical Use of Quantitative Analysis of Bone Scintigraphy to Assess the Involvement of Arthritis Diseases in Patients with Joint Symptoms 1, 2, 3, 4, Jeong Won Lee y , Ki Jin Jung y, Sang Mi Lee * and Sung Hae Chang * 1 Department of Nuclear Medicine, Catholic Kwandong University College of Medicine, International St. Mary’s Hospital, 25, Simgok-ro 100-gil, Seo-gu 22711, Incheon, Korea; [email protected] 2 Department of Orthopedic Surgery, Soonchunhyang University Cheonan Hospital, 31 Suncheonhyang 6-gil, Dongnam-gu, Cheonan 31151, Chungcheongnam-do, Korea; [email protected] 3 Department of Nuclear Medicine. Soonchunhyang University Cheonan Hospital, 31 Suncheonhyang 6-gil, Dongnam-gu, Cheonan 31151, Chungcheongnam-do, Korea 4 Division of Rheumatology, Department of Internal Medicine, Soonchunhyang University Cheonan Hospital, 31 Suncheonhyang 6-gil, Dongnam-gu, Cheonan 31151, Chungcheongnam-do, Korea * Correspondence: [email protected] (S.M.L.); [email protected] (S.H.C.); Tel.: +82-415-703-540 (S.M.L.); +82-41-530-2971 (S.H.C.) These authors contributed equally to this work. y Received: 14 September 2020; Accepted: 23 November 2020; Published: 24 November 2020 Abstract: We aimed to compare the diagnostic ability of quantitative analysis of bone scintigraphy with that of visual analysis for identifying arthritis disease involvement in patients with joint symptoms. We retrospectively included 93 patients with joint symptoms who underwent Tc-99m methylene diphosphonate bone scintigraphy for evaluating arthritis disease involvement. Bone scintigraphy images were visually and quantitatively analyzed using an in-house software by two reviewers. On quantitative analysis, joint uptake ratio was measured for 64 joints in 14 joints areas.
    [Show full text]
  • Osteoporosis and Bone Mineral Density Variant 1: Asymptomatic BMD Screening Or Individuals with Established Or Clinically Suspected Low BMD
    Date of origin: 1998 Last review date: 2016 American College of Radiology ACR Appropriateness Criteria® Clinical Condition: Osteoporosis and Bone Mineral Density Variant 1: Asymptomatic BMD screening or individuals with established or clinically suspected low BMD. 1. All women age 65 years and older and men age 70 years and older (asymptomatic screening) 2. Women younger than age 65 years who have additional risk for osteoporosis, based on medical history and other findings. Additional risk factors for osteoporosis include: a. Estrogen deficiency b. A history of maternal hip fracture that occurred after the age of 50 years c. Low body mass (<127 lb or 57.6 kg) d. History of amenorrhea (>1 year before age 42 years) 3. Women younger than age 65 years or men younger than age 70 years who have additional risk factors, including: a. Current use of cigarettes b. Loss of height, thoracic kyphosis 4. Individuals of any age with bone mass osteopenia or fragility fractures on imaging studies such as radiographs, CT, or MRI 5. Individuals age 50 years and older who develop a wrist, hip, spine, or proximal humerus fracture with minimal or no trauma, excluding pathologic fractures 6. Individuals of any age who develop 1 or more insufficiency fractures 7. Individuals being considered for pharmacologic therapy for osteoporosis 8. Individuals being monitored to: a. Assess the effectiveness of osteoporosis drug therapy b. Follow up medical conditions associated with abnormal BMD Radiologic Procedure Rating Comments RRL* DXA lumbar spine and hip(s) 9 ☢
    [Show full text]
  • Influence of Chronic Recurrent Multifocal Osteomyelitis (CRMO) on Densitometry Measurements Obtained by Dual X-Ray Absorptiometry
    r Biomar ula ke c rs Costantini et al., J Mol Biomark Diagn 2017, 8:4 le o & M D f i DOI: 10.4172/2155-9929.1000341 a o g l Journal of Molecular Biomarkers n a o n r s i u s o J ISSN: 2155-9929 & Diagnosis Research Artilce Open Access Influence of Chronic Recurrent Multifocal Osteomyelitis (CRMO) On Densitometry Measurements Obtained by Dual X-Ray Absorptiometry Danny L Costantini1,3*, Reza Vali1,3, Eman Marie1,3, Mandy Kohli1, Holly Convery2, Martin Charron5, Amer Shammas1,3 and Ronald M Laxer2,4 1Department of Medical Imaging, The Hospital for Sick Children, Toronto, Canada 2Division of Rheumatology, Hospital for Sick Children, Toronto, Canada 3Department of Medical Imaging, University of Toronto, Toronto, Canada 4Department of Pediatrics, University of Toronto, Toronto, Canada 5Brampton Nuclear Services, Brampton, Canada Abstract The incidence of detecting focal chronic recurrent multifocal osteomyelitis (CRMO) lesions on dual-energy x-ray absorptiometry (DXA), and the effect of these lesions on DXA bone mineral density (BMD), bone mineral content (BMC), and their associated Z-scores were retrospectively reviewed. Materials and Methods. The study included 22 patients (14 females, 8 males; median age of 13 years) with CRMO and in whom a total body less head (TBLH) and lumbar spine DXA scan had been obtained. Whole-body bone scintigraphy and MRI were used as the reference standards. Sites involved with CRMO were subsequently detected and DXA measurements were re-measured after removing the sclerotic lesions from the analysis. Results. In total, sclerotic CRMO lesions were detected in 15 of the 22 patients (68%) by DXA, although the number of lesions detected (on a per-lesion analysis) was much less (i.e.
    [Show full text]
  • The Skeletal Survey – 2011 ACR Guidelines – Can We Limit the Images? • 3D Cranial CT Model • Bone Scintigraphy – F-18 PET • MRI, CT and US – Problem Solving Tools
    Skeletal Imaging Strategies and Protocols to the informed physician, the bones tell a story the child is too young or too frightened to tell. Kempe 1962 Jeannette M. Perez-Rossello, MD Department of Radiology Childrens Hospital Boston Harvard Medical School Overview • The Skeletal Survey – 2011 ACR Guidelines – Can we limit the images? • 3D cranial CT model • Bone Scintigraphy – F-18 PET • MRI, CT and US – Problem solving tools • Reporting – Standardized templates Imaging the Skeleton in Suspected Abuse • < 2 yo – Mandatory skeletal survey - using ACR standards – 2 wk follow up skeletal survey or bone scan • 2-5 yo – Skeletal survey or bone scan • >5 yo – Little value in skeletal survey and bone scan – Image areas of clinical concern AAP Policy. Pediatrics 2009, 123:1430-1435 Imaging the Skeleton • Other considerations – MRI and US in selected cases – Image twin of abused infant – Fractures in neglected or sexually assaulted child is low, do skeletal survey in selected cases AAP: Admit child to the hospital for safety until adequate studies performed ACR Standards • Adequate spatial resolution • High signal to noise, sufficient mAs (dose) • Low kVp 50-70 for high contrast • Monitored by radiologist • Cone to anatomic region • Injuries viewed in at least two planes NEW: OBLIQUE VIEWS OF THE CHEST Follow-Up Skeletal Survey • Adds information in 14-61% cases • Identifies new fractures – 62-91% Ribs and CMLs • Confirms suspected fracture • Clarifies a finding, normal variant • Aids dating injuries In patients with normal initial skeletal survey, the follow up study can show additional information in 8-12% of the cases Kleinman. AJR 1996;167:893-896 Zimmerman.
    [Show full text]